{"entity":{"id":"tac01-cldn18-2","kind":"drug","name":"TAC01-CLDN18.2","aka":[],"tldr":"TAC01-CLDN18.2 is an experimental TCR-T cell therapy from Triumvira Immunologics in phase 2 trials, aimed at Claudin 18.2.","summary":"TAC01-CLDN18.2 (TAC01) is a TCR-T cell therapy developed by Triumvira Immunologics. Its target is Claudin 18.2 (the sponsor names Claudin 18.2 (CLDN18.2)). The sponsor states: A genetically engineered autologous T-cell therapy using a T-cell receptor Antigen Coupler (TAC) that directs T cells to CLDN18.2-expressing tumour cells and, once engaged, activates the T cells via the endogenous T-cell receptor. ClinicalTrials.gov describes the intervention as: TAC01-CLDN18.2 preceded by lymphodepletion with fludarabine or clofarabine, cyclophosphamide, and nab-paclitaxel. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT05862324, plans to enrol 113 participants with primary completion expected 2027-08-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of TAC01-CLDN18.2","url":"https://clinicaltrials.gov/search?intr=TAC01"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":["tcr-t"],"targets":["cldn18-2"],"drugs":[],"companies":["triumvira-immunologics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05862324"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"TAC01","modality":"TCR-T cell therapy","mechanism":"A genetically engineered autologous T-cell therapy using a T-cell receptor Antigen Coupler (TAC) that directs T cells to CLDN18.2-expressing tumour cells and, once engaged, activates the T cells via the endogenous T-cell receptor.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tac01-cldn18-2/","neighbours":{"technology":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}],"target":[{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"}],"company":[{"id":"triumvira-immunologics","kind":"company","name":"Triumvira Immunologics","route":"/companies/triumvira-immunologics/"}],"trial":[{"id":"nct05862324","kind":"trial","name":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","route":"/trials/nct05862324/"}]}}